About Can Fite Biopharma Ltd (NASDAQ:CANF)
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company's drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:CANF
- CUSIP: N/A
- Web: www.canfite.co.il
- Market Cap: $28.69 million
- Outstanding Shares: 17,363,000
- 50 Day Moving Avg: $1.70
- 200 Day Moving Avg: $1.77
- 52 Week Range: $1.50 - $2.67
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.37
- P/E Growth: 0.0000
- Annual Revenue: $215,366.00
- Price / Sales: 133.23
- Book Value: $0.23 per share
- Price / Book: 7.18
- Average Volume: 28,573 shs.
- Short Ratio: 5.24
Frequently Asked Questions for Can Fite Biopharma Ltd (NASDAQ:CANF)
What is Can Fite Biopharma Ltd's stock symbol?
Can Fite Biopharma Ltd trades on the NASDAQ under the ticker symbol "CANF."
Where is Can Fite Biopharma Ltd's stock going? Where will Can Fite Biopharma Ltd's stock price be in 2017?
2 brokers have issued 1 year price objectives for Can Fite Biopharma Ltd's shares. Their predictions range from $6.00 to $7.00. On average, they expect Can Fite Biopharma Ltd's stock price to reach $6.50 in the next twelve months. View Analyst Ratings for Can Fite Biopharma Ltd.
Who are some of Can Fite Biopharma Ltd's key competitors?
Some companies that are related to Can Fite Biopharma Ltd include Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Epirus Biopharmaceuticals (EPRS), Humanigen (KBIO), Idenix Pharmaceuticals (IDIX), InterMune (ITMN) and LipoScience (LPDX).
How do I buy Can Fite Biopharma Ltd stock?
Shares of Can Fite Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Can Fite Biopharma Ltd's stock price today?
MarketBeat Community Rating for Can Fite Biopharma Ltd (NASDAQ CANF)MarketBeat's community ratings are surveys of what our community members think about Can Fite Biopharma Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Can Fite Biopharma Ltd stock can currently be purchased for approximately $1.65.
Consensus Ratings for Can Fite Biopharma Ltd (NASDAQ:CANF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$6.50 (293.34% upside)|Consensus Price Target History for Can Fite Biopharma Ltd (NASDAQ:CANF)
Analysts' Ratings History for Can Fite Biopharma Ltd (NASDAQ:CANF)
(Data available from 10/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/17/2017||Maxim Group||Set Price Target||Buy||$7.00||N/A|
|8/10/2017||HC Wainwright||Set Price Target||Buy||$6.00||Low|
Earnings History for Can Fite Biopharma Ltd (NASDAQ:CANF)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Can Fite Biopharma Ltd (NASDAQ:CANF)
Current Year EPS Consensus Estimate: $-0.3000 EPS
Next Year EPS Consensus Estimate: $-0.4900 EPS
Dividend History for Can Fite Biopharma Ltd (NASDAQ:CANF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Can Fite Biopharma Ltd (NASDAQ:CANF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Can Fite Biopharma Ltd (NASDAQ:CANF)
Latest Headlines for Can Fite Biopharma Ltd (NASDAQ:CANF)
Can Fite Biopharma Ltd (CANF) Chart for Wednesday, October, 18, 2017